Home Featured Page 165

Featured

Latest

Out of This World: Why AI Belongs Beside the Therapist

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Utah’s Quiet Revolution: Why HB 390 May Be the Most Significant Psychedelic Legislation of 2026

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Wesana Announces Second Quarter 2022 Financial Results

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops...

MindMed Completes 1-for-15 Reverse Share Split

PT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY...

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic...

EDITOR PICKS

Out of This World: Why AI Belongs Beside the Therapist

Psychedelic Policy Briefing: June 11, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Utah’s Quiet Revolution: Why HB 390 May Be the Most Significant Psychedelic Legislation of 2026

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Wesana Announces Second Quarter 2022 Financial Results

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops...

MindMed Completes 1-for-15 Reverse Share Split

PT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY...

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic...

EDITOR PICKS

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY